Abstract
NY-ESO-1 mRNA expression was investigated in advanced prostate cancer by conventional and quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR). NY-ESO-1 mRNA was detected in 20 of 53 (38%) tumor specimens. Four of 15 (27%) stage C, 1 of 3 stage D1 (33%) and 15 of 35 (43%) stage D2 prostate cancers were positive. The presence of NY-ESO-1 antibodies was evaluated in sera from a panel of 218 patients with prostate cancer, including the 53 patients whose tumors were examined for NY-ESO-1 mRNA expression. NY-ESO-1 antibodies were detected in 1 of 30 (3.3%) stage D1 and 9 of 110 (8.2%) stage D2 patients, whereas none of the 78 patients with localized prostate cancer (stages A, B and C) had detectable NY-ESO-1 antibodies. Of the 53 patients whose tumors were examined for NY-ESO-1 mRNA expression, 2 of 20 patients with NY-ESO-1 mRNA-positive tumors had NY-ESO-1 antibodies. No antibody was found in the sera of 32 patients with NY-ESO-1 mRNA-negative tumors, with the exception of one patient with regional lymph node metastasis (stage D1). CD8 T cell responses specific to NY-ESO-1 were detected in two of three patients with NY-ESO-1 antibodies.
| Original language | English |
|---|---|
| Pages (from-to) | 1-12 |
| Number of pages | 12 |
| Journal | Cancer immunity : a journal of the Academy of Cancer Immunology |
| Volume | 3 |
| Publication status | Published - Jul 31 2003 |
Fingerprint
Keywords
- Human
- Immunity
- mRNA
- NY-ESO-1
- Prostate cancer
- RT-PCR
ASJC Scopus subject areas
- Cancer Research
- Immunology
Cite this
NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. / Nakada, Tetsuya; Noguchi, Yuji; Satoh, Shuichiro; Ono, Toshiro; Saika, Takashi; Kurashige, Takushi; Gnjatic, Sacha; Ritter, Gerd; Chen, Yao Tseng; Stockert, Elisabeth; Nasu, Yasutomo; Tsushima, Tomoyasu; Kumon, Hiromi; Old, Lloyd J.; Nakayama, Eiichi.
In: Cancer immunity : a journal of the Academy of Cancer Immunology, Vol. 3, 31.07.2003, p. 1-12.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer
AU - Nakada, Tetsuya
AU - Noguchi, Yuji
AU - Satoh, Shuichiro
AU - Ono, Toshiro
AU - Saika, Takashi
AU - Kurashige, Takushi
AU - Gnjatic, Sacha
AU - Ritter, Gerd
AU - Chen, Yao Tseng
AU - Stockert, Elisabeth
AU - Nasu, Yasutomo
AU - Tsushima, Tomoyasu
AU - Kumon, Hiromi
AU - Old, Lloyd J.
AU - Nakayama, Eiichi
PY - 2003/7/31
Y1 - 2003/7/31
N2 - NY-ESO-1 mRNA expression was investigated in advanced prostate cancer by conventional and quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR). NY-ESO-1 mRNA was detected in 20 of 53 (38%) tumor specimens. Four of 15 (27%) stage C, 1 of 3 stage D1 (33%) and 15 of 35 (43%) stage D2 prostate cancers were positive. The presence of NY-ESO-1 antibodies was evaluated in sera from a panel of 218 patients with prostate cancer, including the 53 patients whose tumors were examined for NY-ESO-1 mRNA expression. NY-ESO-1 antibodies were detected in 1 of 30 (3.3%) stage D1 and 9 of 110 (8.2%) stage D2 patients, whereas none of the 78 patients with localized prostate cancer (stages A, B and C) had detectable NY-ESO-1 antibodies. Of the 53 patients whose tumors were examined for NY-ESO-1 mRNA expression, 2 of 20 patients with NY-ESO-1 mRNA-positive tumors had NY-ESO-1 antibodies. No antibody was found in the sera of 32 patients with NY-ESO-1 mRNA-negative tumors, with the exception of one patient with regional lymph node metastasis (stage D1). CD8 T cell responses specific to NY-ESO-1 were detected in two of three patients with NY-ESO-1 antibodies.
AB - NY-ESO-1 mRNA expression was investigated in advanced prostate cancer by conventional and quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR). NY-ESO-1 mRNA was detected in 20 of 53 (38%) tumor specimens. Four of 15 (27%) stage C, 1 of 3 stage D1 (33%) and 15 of 35 (43%) stage D2 prostate cancers were positive. The presence of NY-ESO-1 antibodies was evaluated in sera from a panel of 218 patients with prostate cancer, including the 53 patients whose tumors were examined for NY-ESO-1 mRNA expression. NY-ESO-1 antibodies were detected in 1 of 30 (3.3%) stage D1 and 9 of 110 (8.2%) stage D2 patients, whereas none of the 78 patients with localized prostate cancer (stages A, B and C) had detectable NY-ESO-1 antibodies. Of the 53 patients whose tumors were examined for NY-ESO-1 mRNA expression, 2 of 20 patients with NY-ESO-1 mRNA-positive tumors had NY-ESO-1 antibodies. No antibody was found in the sera of 32 patients with NY-ESO-1 mRNA-negative tumors, with the exception of one patient with regional lymph node metastasis (stage D1). CD8 T cell responses specific to NY-ESO-1 were detected in two of three patients with NY-ESO-1 antibodies.
KW - Human
KW - Immunity
KW - mRNA
KW - NY-ESO-1
KW - Prostate cancer
KW - RT-PCR
UR - http://www.scopus.com/inward/record.url?scp=3042687137&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=3042687137&partnerID=8YFLogxK
M3 - Article
C2 - 12889868
AN - SCOPUS:3042687137
VL - 3
SP - 1
EP - 12
JO - Cancer immunology research
JF - Cancer immunology research
SN - 2326-6066
ER -